Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04348656 · ClinicalTrials.gov registry record · Phase 3
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
A Phase 3 study, sponsored by Hamilton Health Sciences Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 940
- Enrollment target
NCT04348656: Clinical Trial Phase 3 study, sponsored by Hamilton Health Sciences Corporation.
NCT04348656 is a Phase 3 study that was terminated before completion, run by Hamilton Health Sciences Corporation. The registered enrollment target is 940 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04348656, a Phase 3 study, was terminated before completion, sponsored by Hamilton Health Sciences Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 940 participants
- Enrollment target
Study Summary
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection. The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay. This pan-Canadian clinical trial has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.
Primary Outcome
Endpoint of the need for intubation or patient death
Interventions
- BIOLOGICAL Convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 940 participants |
| Start Date | 2020-03-14 |
| Est. Completion | 2021-06-16 |
| Phase | Phase 3 |
Why NCT04348656 stopped before completion
NCT04348656 is an interventional study that assigns participants to a tested intervention. The registered 940 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 1 intervention - of which Convalescent plasma is the first listed.
NCT04348656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04348656 about?
NCT04348656 is a clinical study titled "CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)". There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of conva...
What is the current status of trial NCT04348656?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 940 participants. The study started on 2020-03-14. Estimated completion is 2021-06-16.
What interventions are being tested in trial NCT04348656?
The interventions under investigation include: Convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04348656?
This trial is sponsored by Hamilton Health Sciences Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04348656's enrollment target sits among peer trials
940 337th of 2000 higher than 1,663 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI